Lilly and Novo paid 250,000+ GLP-1 prescribers since 2018, more than any Rx class, showing how heavily pharma will invest in HCP marketing to differentiate brands.

56% of US GLP-1 users who are trading up to premium food and beverages say it's because they eat less overall, so they can afford higher-quality food, according to a November survey from The New Consumer and Coefficient Capital.

While consumers are willing to pay cash for the pricey drugs, they’ll also come to expect the consistency in value of a premium purchase.

US ecommerce is poised to enter a phase of mature and stable growth, but AI remains a wild card that could significantly alter the trajectory of retail’s online shift.

11% of US adults currently use a GLP-1 medication, up from just 3% two years earlier, according to a July report from Gallup.

GLP-1s are creating a new consumer economy that reaches beyond healthcare. As treatment becomes easier to access, brands must balance growth opportunities with misinformation, fragmented support, and rising expectations for lifestyle services.

On today’s podcast, we go beyond the headlines to explore what’s driving the latest wave of GLP-1 momentum, why this represents a lasting shift rather than just another healthcare trend, the biggest misconception retailers still have about how these drugs are changing consumer behavior, and which parts of the retail playbook need to be rewritten as consumers change how they eat, shop, and live. Tune in for a discussion featuring Vice President of Content and host Suzy Davidkhanian, along with Senior Analysts Rajiv Leventhal and Rachel Wolff.

The next phase of GLP-1 marketing competition may hinge on whether brands convince consumers to stay on treatment or build habits that last after stopping them.

Wearables are shifting from fitness trackers to connected healthcare platforms. The value of AI, clinician access, and health data integration is expanding, as high costs risk excluding consumers who need these tools the most.

Wegovy pill's lead over Foundayo signals drug marketers need to build consumer and healthcare provider brand awareness before launch.

Many telehealth sites skipped key check-ins with patients yet still prescribed GLP-1s, inviting regulatory scrutiny.

Medicare weight loss drug program will lower prescription costs for many older adults, but eligibility and prior approvals may leave patients relying on providers and pharmacies for answers.

AI visibility for pharma brands won't replace physician outreach or advertising, but it reinforces credibility.

The next wave of retail growth is coming from younger shoppers. They blend stores, social commerce, and AI with ease. But rising expectations around trust, transparency, and control are reshaping the path to purchase.

Oura courts GLP-1 users with free ring sizing kit via Lilly tie-up, signaling how drugmakers are pairing therapies with digital health tools to boost engagement and long-term adherence.

CVS MinuteClinic’s new $49 virtual GLP-1 program matches Walgreens on price, but differentiation will still be difficult in a crowded telehealth weight loss market.

Consumers are treating health and wellness as essential spending even in a tough economy. Social media and wellness culture are fueling demand for supplements, healthier food, and longevity products. At the same time, misinformation and pressure to stay healthy are increasing.

Close to 40% are familiar with the concept of healthspan and are actively building the foundation for healthier aging.

Backlash over Medvi’s telehealth business after a NYT report signals increasing scrutiny of online health ads.

Novo is testing tiered subscriptions to boost Wegovy adherence—but whether patients stay on their meds will hinge on post-prescription support from its telehealth partners.